X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse AMAR REMEDIES with HYPERMARCAS SA - Brazil - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AMAR REMEDIES vs HYPERMARCAS (Brazil) - Comparison Results

HYPERMARCAS (Brazil)
   Change

Hypermarcas SA is a leading consumer goods company in Brazil. The company is present in pharmaceuticals and personal care. The company's pharmaceuticals products include over-the-counter medications, generic drugs and prescription medications. The c... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 AMAR REMEDIES   HYPERMARCAS
EQUITY SHARE DATA
    AMAR REMEDIES
Jun-12
HYPERMARCAS
Dec-14
AMAR REMEDIES/
HYPERMARCAS
5-Yr Chart
Click to enlarge
High Rs164431-   
Low Rs86316-   
Sales per share (Unadj.) Rs261.6147.2-  
Earnings per share (Unadj.) Rs17.413.0-  
Cash flow per share (Unadj.) Rs22.316.4-  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs100.7235.1-  
Shares outstanding (eoy) m26.16635.00-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.52.5 18.8%   
Avg P/E ratio x7.228.8 24.9%  
P/CF ratio (eoy) x5.622.8 24.6%  
Price / Book Value ratio x1.21.6 78.1%  
Dividend payout %00-   
Avg Mkt Cap Rs m3,270237,134 1.4%   
No. of employees `000NA12.9 0.0%   
Total wages/salary Rs m1634,573 3.6%   
Avg. sales/employee Rs ThNM7,225.3-  
Avg. wages/employee Rs ThNM353.5-  
Avg. net profit/employee Rs ThNM636.1-  
INCOME DATA
Net Sales Rs m6,84493,460 7.3%  
Other income Rs m211,578 1.3%   
Total revenues Rs m6,86595,037 7.2%   
Gross profit Rs m1,13122,557 5.0%  
Depreciation Rs m1282,187 5.9%   
Interest Rs m39811,902 3.3%   
Profit before tax Rs m62610,045 6.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-50-200 25.0%   
Tax Rs m1211,618 7.5%   
Profit after tax Rs m4558,228 5.5%  
Gross profit margin %16.524.1 68.5%  
Effective tax rate %19.316.1 120.0%   
Net profit margin %6.68.8 75.5%  
BALANCE SHEET DATA
Current assets Rs m4,90496,355 5.1%   
Current liabilities Rs m3,58159,690 6.0%   
Net working cap to sales %19.339.2 49.3%  
Current ratio x1.41.6 84.8%  
Inventory Days Days12452 241.0%  
Debtors Days Days100121 82.6%  
Net fixed assets Rs m1,68933,290 5.1%   
Share capital Rs m262105,102 0.2%   
"Free" reserves Rs m2,3580-   
Net worth Rs m2,635149,296 1.8%   
Long term debt Rs m50761,388 0.8%   
Total assets Rs m6,862277,343 2.5%  
Interest coverage x2.61.8 139.5%   
Debt to equity ratio x0.20.4 46.8%  
Sales to assets ratio x1.00.3 296.0%   
Return on assets %12.47.3 171.3%  
Return on equity %17.35.5 313.3%  
Return on capital %31.010.3 300.3%  
Exports to sales %4.00-   
Imports to sales %00-   
Net fx Rs m2710-   
CASH FLOW
From Operations Rs m-31313,260 -2.4%  
From Investments Rs m-4891,362 -35.9%  
From Financial Activity Rs m769-1,222 -62.9%  
Net Cashflow Rs m-3313,402 -0.2%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for HYPERMARCAS (Brazil) is Brazil Reais. All data has been converted at 19.97 Rs / BRL

Compare AMAR REMEDIES With: P&G (US)  UNILEVER PLC. (UK)  

Compare AMAR REMEDIES With: K.S.OILS LTD  BAJAJ CORP  PIDILITE INDUSTRIES  KARUTURI GLOBAL  RELAXO FOOTWEARS  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views On News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AMAR REMEDIES SHARE PRICE


Dec 11, 2013 (Close)

TRACK AMAR REMEDIES

  • Track your investment in AMAR REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AMAR REMEDIES 5-YR ANALYSIS

COMPARE AMAR REMEDIES WITH

MARKET STATS